
Excellence in Pediatrics is a non-profit association dedicated to advancing pediatric healthcare.
Rue des Vignerons 18, 1110 Morges 1 (VD), Switzerland
email: secretariat@ineip.org
tel. +41 43 21 55 937
Stay informed with the latest updates, reports and prevention-focused insights from the Excellence in Pediatrics and its global initiatives.
This archive brings together past newsletters from across our work, spanning pediatric education, rare disease awareness and lifecourse prevention. Browse previous editions to catch up on key updates, resources and news from EiP and its partners.
.webp)
How to build a baseline assessment and monitor alpha-mannosidosis over time with validated clinical scales. A Think Rare webinar, 28 October 2026.
.webp)
From first clue to confirmed diagnosis: live webinars with Dr. Christina Lampe and Dr. Neena Champaigne on recognizing, referring and testing rare disease.
.webp)
Mild alpha-mannosidosis is easily overlooked. Dr. Karolina Stepien and Dr. João Durães on the subtle signals that should prompt earlier action.
.webp)
Three free Think Rare webinars on alpha-mannosidosis: recognizing early signs, spotting mild forms, and monitoring progression and treatment impact.
.webp)
Dr. Dipak Ram on building a multidisciplinary CLN2 service, delivering the diagnosis, and tracking disease progression. A Think Rare Program webinar.

RSV drives pneumococcal disease and shapes lung function into adulthood. Why its lasting burden is the strongest case for early universal prevention.
.webp)
Think Rare webinar with Dr. Marina Trivisano and Dr. Pasquale Striano on telling CLN2 Batten disease apart from epilepsy, autism, and developmental delay.

Progressive neurodegenerative disorders in children are rare but often diagnosed too late. This webinar explores why earlier recognition matters for clinicians.

Think Rare expands to CLN2 (Batten Disease), a rare neurodegenerative disease in young children, with new live webinars coming up.

Free vaccines don't guarantee equal access. Why child poverty drives vaccination inequity, and why reducing it is a prerequisite.

The tools for RSV prevention work; coverage decides the impact. Multi-country evidence on reaching every infant, from the 2025 LifeCourse Prevention Summit.

When communities are engaged as partners, vaccination programs work better. Insights from the 2025 LifeCourse Summit on co-design, engagement, and equity.

Most infants hospitalized with RSV are otherwise healthy. Why universal prevention outperforms targeted strategies - insights from the 2025 LifeCourse Summit.

Why do vaccination systems fail the communities they serve? Insights from the 2025 LifeCourse Prevention Summit on trust, access, and the case for system change